Debtors Exam for CVBT
Zhittya Genesis Medicine Inc., (formerly known as Zhittya Regenerative Medicine), competitor to Cardiovascular Biotherapeutics Inc., has announced its CEO, Daniel C. Montano, has been awarded an over $1 million legal judgement, confirmed by the US Federal Court, against CVBT and its new name, Venturis Therapeutics.
Mr. Dan Montano is now pursuing the involuntary collections of his judgements against CVBT.
Zhittya Genesis Medicine also announced that ALL legal allegations made against Zhittya Genesis Medicine have been DISMISSED by the judge.
After seven years of lawsuits by CVBT against Zhittya it is clear that CVBT has come out as the ultimate loser after this judgement against them for $1 million. In all this time, CVBT has FAILED TO CONDUCT CLINICAL TRIALS, MANUFACTURE THE DRUG, OR PAID ANY PART OF ITS $30 MILLION IN DELINQUENT BILLS.
